tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Covalon Technologies’ VALGuard® Shows Promising Results in Reducing CLABSIs

Story Highlights
Covalon Technologies’ VALGuard® Shows Promising Results in Reducing CLABSIs

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest update is out from Covalon Technologies ( (TSE:COV) ).

Covalon Technologies announced the publication of a peer-reviewed clinical study demonstrating the effectiveness of its VALGuard® Vascular Access Line Guard in significantly reducing central line-associated bloodstream infections (CLABSIs) in a pediatric hospital setting. The study, conducted at the Children’s Hospital at Montefiore, showed a 100% reduction in CLABSI rates in the Pediatric Critical Care Unit and a 53% reduction in Acute Care Units, highlighting the product’s potential to enhance infection prevention protocols. This publication supports Covalon’s growth strategy in the vascular access and surgical consumables sector and reinforces the importance of advanced technologies in preventing hospital-acquired infections.

The most recent analyst rating on (TSE:COV) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on Covalon Technologies stock, see the TSE:COV Stock Forecast page.

Spark’s Take on TSE:COV Stock

According to Spark, TipRanks’ AI Analyst, TSE:COV is a Outperform.

Covalon Technologies’ overall stock score is driven by strong financial performance and positive earnings call highlights, including sequential revenue growth and international expansion. Technical analysis and valuation present moderate scores, reflecting mixed market sentiment and valuation metrics.

To see Spark’s full report on TSE:COV stock, click here.

More about Covalon Technologies

Covalon Technologies is a leading medical device company focused on improving patient outcomes through innovative medical products and technologies. The company’s expertise includes advanced wound care, vascular access, and surgical consumables, with a strong emphasis on enhancing healing, reducing healthcare-associated infections, and protecting skin integrity.

Average Trading Volume: 22,513

Technical Sentiment Signal: Sell

Current Market Cap: C$59.77M

For a thorough assessment of COV stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1